Target identification and validation is a major challenge in the pharmaceutical industry, with many promising treatments failing in the clinic for efficacy or target-related safety issues. The reason is usually that the underlying hypothesis turns out to be wrong, or there are unwanted consequences to modulating the target. Comprehensive diligence around a target before starting a discovery program can make the difference between success and failure. In this point of view, we discuss how Syngene’s Target Assessment service enables informed decision-making resulting in increased clinical and commercial success.